Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is expected to see positive growth in the near future through its ongoing Phase 3 trials and potential for label expansion for its marketed products, as well as its focus on capturing a significant portion of the non-Medicare CKD market. Despite potential risks, the company's strong financial standing and potential billion-dollar peak sales for Ibsrela make it a promising investment opportunity. With analysts' upgraded ratings and a new price target set, the company is poised for success in the biopharmaceutical industry.

Bears say

Ardelyx is steadily advancing its pipeline with its IBSRELA and XPHOZAH drugs, but increasing expenses and potential pull-forward of sales raise concerns about the company's growth potential. Additionally, the company's IP strategy is encouraging, but with a negative outlook on the stock, the potential for success with its Phase 3 ACCEL trial in CIC patients is still uncertain and not factored into the valuation. While the company's target of 110 trial sites for IBSRELA is ambitious, it may not translate to immediate revenue growth.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.